Objective: To evaluate the effectiveness of guanfacine extended-release (GXR) versus placebo as adjunct therapy to usual care stimulant therapy in improving executive function in children aged 6 to 12 years diagnosed with ADHD. Method: In this single center, double-blind placebo-controlled crossover trial, subjects continued to take their psychostimulant and were randomly assigned at baseline to receive active treatment or placebo first. Efficacy measures included Behavioural Rating Inventory of Executive Function (BRIEF-P), ADHD Rating Scale IV (ADHD-RS IV), and Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) scales. Safety measures included adverse events and vital signs. Results: Significant benefits of GXR plus psychostimulant were observed on BRIEF-P (p value = .0392), ADHD-RS-IV (p < .0001), CGI-S (p = .0007), and CGI-I (p = .003). There were no serious adverse events and no new safety signals. Conclusion: Use of GXR as adjunctive therapy to stimulant therapy significantly improves executive function in children with ADHD.
AdlerL.DirksB.DeasP. F.RaychaudhuriA.Dauphin MatthewR.LasserR. A.WeislerR. H. (2013). Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: Results from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 74, 694-702.
2.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
3.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
4.
BarkleyR. A. (1997). Behavioural inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychological Bulletin, 121, 65-94.
5.
BiedermanJ.MelmedR. D.PatelA.McBurnettK.DonahueJ.LyneA. (2008). Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectrums, 13, 1047-1055.
6.
BiedermanJ.MelmedR. D.PatelA.McBurnettK.KonowJ.LyneA.SchererN. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121(1), e73-e84. doi:10.1542/peds.2006-3695
7.
BiedermanJ.SpencerT. W. T. (2004). Evidenced-based pharmacotherapy for attention-deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 7, 77-97.
8.
BoellnerS.PennickM.FiskeK.LyneA.ShojaeiA. (2007). Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy, 27, 1253-1262. doi:10.1592/phco.27.9.1253
9.
BrownT. (2006). Executive functions and attention deficit hyperactivity disorder: Implications of two conflicting views. International Journal of Disability, Development and Education, 53, 35-46.
10.
DuPaulG.PowerT.AnastopoulosA.ReidR. (1998). ADHD Rating Scale IV: Checklists, Norms and Clinical Interpretation. New York, NY: Guilford Press.
11.
FindlingR. L.GinsbergL.JainR.GaoJ. (2009). Effectiveness, safety, and tolerability of lisdexamfetamine Dimesylate in children with attention-deficit/hyperactivity disorder: An open-label, dose optimization study. Journal of Child and Adolescent Psychopharmacology, 19, 649-662.
12.
FloetA. M. W.ScheinerC.GrossmanL. (2010). Attention-deficit/hyperactivity disorder. Pediatrics in Review, 31(2), 56-69. doi:10.1542/pir.31-2-56
13.
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. (2004). Pediatrics, 114, 555-576.
14.
GauS.-F.ShangC.-Y. (2010). Improvement of executive functions in boys with attention deficit hyperactivity disorder: An open-label follow up study with once-daily atomoxetine. International Journal of Neuropsychopharmacology, 13, 243-256.
15.
GioiaG. A.IsquithP.GuyS.KenworthyL. (2000). Behaviour Rating Inventory of Executive Function (BRIEF): Professional Manual. PAR, Lutz, FL.
16.
GioiaG. A.IsquithP.RetzlaffP.EspyK. A. (2002). Confirmatory factor analysis of the Behaviour Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychology, 8, 249-257.
17.
GroupT. M. C. (1999). A 14 month randomized clinical trial of treatment strategis for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 56, 1073-1086.
18.
GuyW. (1976). The Clinical Global Impression Scale. In GuyW. (Ed.), ECDEU Assessment Manual for Psychopharmacology (pp. 218-222). Rockville, MD: U.S. Department of Health, Education, and Welfare.
19.
HaleJ.ReddyL.Semrud-ClikemanM.HainL.WhitakerJ.MorleyJ.JonesN. (2011). Executive impairment determines ADHD medication response: Implications for academic achievement. Journal of Learning Disabilities, 44, 196-212.
20.
HervasA.HussM.JohnsonM.McNicholasF.van StralenJ.SreckovicS.RobertsonB. (2014). Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, phase III trial. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 24, 1861-1872. doi:10.1016/j.euroneuro.2014.09.014
21.
HinshawS.BuhrmesterD.HellerT. (1989). Anger control in response to verbal provocation: Effects of stimulant medication for boys with ADHD. Journal of Abnormal Child Psychology, 17, 393-407.
22.
HosenbocusS.ChahalR. (2012). Management in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 21, 223-229.
23.
MaresD.McLuckieA.SchwartzM.SainiM. (2007). Executive function impairments in children with attention-deficit hyperactivity disorder: Do they differ between school and home environments?Canadian Journal of Psychiatry, 52, 527-534.
24.
PolanczykG.deLimaM. S.HortaB. L.BiedermanJ.RohdeL. A. (2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. American Journal of Psychiatry, 164, 942-948.
25.
PosnerK.BrentD.LucasC.GouldM.StanleyB.BrownG.MannJ. (2010). Columbia-Suicide Severity Rating Scale (C-SSRS) (Children’s Since Last Visit). New York, NY: The Research Foundation for Mental Hygiene.
26.
PostnerK.BrentD.LucasC.GouldM.StanleyB.BrownG.MannJ. (2010). Columbia-Suicide Severity Rating Scale (C-SSRS) (Children’s Lifetime/ Recent). New York, NY: The Research Foundation for Mental Hygiene
27.
PosnerK.BrownG.StanleyB. (2011). Columbia-Suicide everity Rating Scale: Initial validity and internal consistency finding from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168, 1266-1277.
28.
RobertL.FindlingM. D.LawrenceD.GinsbergM. D.RakeshJ.GaoJ. (2009). Effectiviness, safety and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity. Journal of Child and Adolescent, 19, 649-662.
29.
SalleeF. R.LyneaWigalT.McGoughJ. J. (2009). Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorderJournal of Child and Adolescent Psychopharmacology, 19, 215-226. doi:10.1089/cap.2008.0080
30.
SalleeF. R.McgoughJ.WigalT.DonahueJ.LyneA.BiedermanJ. (2009). Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry, 48, 155-165. doi:10.1097/CHI.0b013e318191769e
SpencerT. J.GreenbaumM.GinsbergL. D.MurphyW. R. (2009). Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19, 501-510. doi:10.1089/cap.2008.0152
33.
StrineT.LeseneC.OkoroC.McGuireI.ChapmanD.BallusL.MokdadA. (2006). Emotional and behavioural difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Preventing Chronic Disease, 3(2), 1-10.
34.
TurgayA.GinsbergL.SarkisE.JainR.AdeyiB.GaoJ.FindlingR. L. (2010). Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. Journal of Child and Adolescent Psychopharmacology, 20, 503-511. doi:10.1089/cap.2009.0110
35.
van StralenJ. (2016). Emotional dysregulation in children with attention-deficit/hyperactivity disorder. ADHD Attention Deficit and Hyperactivity Disorders, 8, 175-187. doi:10.1007/s12402-016-0199-0
36.
VitielloB. (2001). Methylpyhenidate in the treatment of children with attention-deficit hyperactivity disorder. Canadian Medical Association Journal, 165, 1505-1506.
37.
WilensT. E.BuksteinO.BramsM.CutlerA. J.ChildressA.RuginoT.YouchaS. (2012). A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 51(1), 74-85.e2. doi:10.1016/j.jaac.2011.10.012
38.
WilensT. E.SpencerT.BiedermanJ.WozniakJ.ConnorD. (1995). Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 110-112. doi:10.1097/00004583-199501000-00021
